We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Cantrixil

News List

Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB prnasia
March 02, 2021
Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB (STO: OASM).
Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals prnasia
December 09, 2020
Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, is pleased to share top-line final data from its phase I study of Cantrixil (TRX-E-002-1) in patients with persistent or recurrent ovarian cancer (NCT02903771).
Australian cancer specialists may hold key to next advancement in ovarian cancer treatment pharmaasia
September 05, 2017
Three leading Australia cancer treatment centres are at the forefront of a drug trial that could see the next major advancement in ovarian cancer therapy.